BR112020026112A2 - Proteínas heterodiméricas e usos das mesmas - Google Patents

Proteínas heterodiméricas e usos das mesmas Download PDF

Info

Publication number
BR112020026112A2
BR112020026112A2 BR112020026112-2A BR112020026112A BR112020026112A2 BR 112020026112 A2 BR112020026112 A2 BR 112020026112A2 BR 112020026112 A BR112020026112 A BR 112020026112A BR 112020026112 A2 BR112020026112 A2 BR 112020026112A2
Authority
BR
Brazil
Prior art keywords
protein
receptor
human
amino acid
antigen
Prior art date
Application number
BR112020026112-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Taylor Schreiber
George Fromm
Suresh De Silva
Original Assignee
Shattuck Labs, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs, Inc. filed Critical Shattuck Labs, Inc.
Publication of BR112020026112A2 publication Critical patent/BR112020026112A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112020026112-2A 2018-06-21 2019-06-21 Proteínas heterodiméricas e usos das mesmas BR112020026112A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862688167P 2018-06-21 2018-06-21
US62/688.167 2018-06-21
US201862703248P 2018-07-25 2018-07-25
US62/703.248 2018-07-25
PCT/US2019/038451 WO2019246508A1 (en) 2018-06-21 2019-06-21 Heterodimeric proteins and uses thereof

Publications (1)

Publication Number Publication Date
BR112020026112A2 true BR112020026112A2 (pt) 2021-04-06

Family

ID=68983045

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020026112-2A BR112020026112A2 (pt) 2018-06-21 2019-06-21 Proteínas heterodiméricas e usos das mesmas

Country Status (10)

Country Link
US (3) US10995127B2 (https=)
EP (1) EP3810172A4 (https=)
JP (3) JP7439372B2 (https=)
KR (1) KR20210025054A (https=)
CN (1) CN112566650A (https=)
AU (1) AU2019290192A1 (https=)
BR (1) BR112020026112A2 (https=)
CA (1) CA3103975A1 (https=)
MX (1) MX2020014031A (https=)
WO (1) WO2019246508A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210025054A (ko) * 2018-06-21 2021-03-08 샤턱 랩스 인코포레이티드 이형이량체 단백질 및 이의 용도
AU2020340424A1 (en) * 2019-08-30 2022-03-31 Shattuck Labs, Inc. Chimeric proteins in autoimmunity
WO2021202354A1 (en) * 2020-03-30 2021-10-07 Proviva Therapeutics (Hong Kong) Limited Il-2/il-15 compositions and methods of use thereof
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2022241058A1 (en) 2021-05-12 2022-11-17 Applied Biomedical Science Institute Methods of screening and expression of disulfide-bonded binding polypeptides
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
WO2023205738A2 (en) * 2022-04-20 2023-10-26 Neptune Biosciences Llc Orthogonal il-21 receptor/cytokine systems
CA3256783A1 (en) 2022-05-16 2023-11-23 Enkefalos Biosciences, Llc Blood-brain barrier translocation peptides and associated molecules and their methods of use
WO2024019984A1 (en) * 2022-07-18 2024-01-25 Cargo Therapeutics, Inc. Cytokine receptor switch polypeptides and uses thereof
EP4619430A1 (en) 2022-11-16 2025-09-24 Applied Biomedical Science Institute Fusion polypeptides and binding peptides and methods for producing and using same
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2025133115A1 (en) * 2023-12-21 2025-06-26 Ose Immunotherapeutics Lipid-based nanoparticles comprising il-35
WO2025140436A1 (zh) * 2023-12-27 2025-07-03 上海药明生物技术有限公司 重组il-27蛋白及其制备方法
CN117986386B (zh) * 2024-02-06 2024-11-29 康立泰生物医药(青岛)有限公司 重组人白细胞介素-35及其制备方法和应用
US20260035414A1 (en) * 2024-08-01 2026-02-05 Twilight Bioscience, Inc. Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE196297T1 (de) * 1994-05-18 2000-09-15 Synthetic Peptides Inc Heterodimere trägerzusammensetzung von immunogenen polypeptiden und verfahren zu deren verwendung
IT1274350B (it) * 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
ATE295887T1 (de) 1996-02-20 2005-06-15 Applied Research Systems Heterodimerebildende hybrid-proteine
EP1489100B1 (en) * 1997-12-08 2016-06-15 Merck Patent GmbH Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4793971B2 (ja) * 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
ES2381650T3 (es) * 2000-08-08 2012-05-30 Zymogenetics, Inc. Receptores de citoquinas Zcytor11 solubles
ATE498633T1 (de) * 2004-07-09 2011-03-15 Variety Children S Hospital D B A Miami Children S Hospital Materialien und verfahren zur stimulierung des immunsystems
EP2072527A1 (en) * 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
KR20120108967A (ko) * 2009-09-16 2012-10-05 제넨테크, 인크. 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
CN102958942A (zh) 2009-12-29 2013-03-06 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
EP4012714A1 (en) * 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CA2902739C (en) * 2013-03-15 2022-11-22 Xencor, Inc. Heterodimeric proteins
US10017545B2 (en) * 2013-06-03 2018-07-10 University Of Maryland, College Park Compositions and vaccines comprising vesicles and methods of using the same
WO2017019623A2 (en) * 2015-07-26 2017-02-02 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
HK1243629A1 (zh) 2014-09-17 2018-07-20 基因泰克公司 包含抗her2抗体和吡咯并苯并二氮杂䓬的免疫缀合物
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
CA2978186A1 (en) * 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
RU2766200C1 (ru) 2015-10-01 2022-02-09 Хит Байолоджикс, Инк. Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков
US10954301B2 (en) 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
CN118307682A (zh) * 2016-09-27 2024-07-09 埃皮辛特瑞柯斯公司 免疫调节性融合蛋白
US12447213B2 (en) * 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
MX2019009812A (es) * 2017-02-27 2019-10-14 Shattuck Labs Inc Proteinas quimericas basadas en tigit y light.
KR20210025054A (ko) * 2018-06-21 2021-03-08 샤턱 랩스 인코포레이티드 이형이량체 단백질 및 이의 용도
US11098093B2 (en) * 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
AU2020340424A1 (en) * 2019-08-30 2022-03-31 Shattuck Labs, Inc. Chimeric proteins in autoimmunity

Also Published As

Publication number Publication date
JP7452932B2 (ja) 2024-03-19
WO2019246508A1 (en) 2019-12-26
MX2020014031A (es) 2021-05-12
AU2019290192A1 (en) 2021-01-07
JP2021527700A (ja) 2021-10-14
JP2024057087A (ja) 2024-04-23
CA3103975A1 (en) 2019-12-26
JP2023116718A (ja) 2023-08-22
CN112566650A (zh) 2021-03-26
US10995127B2 (en) 2021-05-04
EP3810172A4 (en) 2022-04-20
US20200079831A1 (en) 2020-03-12
EP3810172A1 (en) 2021-04-28
KR20210025054A (ko) 2021-03-08
US11780897B2 (en) 2023-10-10
US20230220030A1 (en) 2023-07-13
US20210214409A1 (en) 2021-07-15
JP7439372B2 (ja) 2024-02-28

Similar Documents

Publication Publication Date Title
US11780897B2 (en) Heterodimeric proteins and uses thereof
JP7303254B2 (ja) Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法
JP7620045B2 (ja) Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
US10988517B2 (en) Heterodimeric proteins for modulating gamma delta T cells
US11643447B2 (en) Heterodimeric proteins for modulating gamma delta T cells
US20230416333A1 (en) Homodimeric and heterodimeric proteins comprising butyrophilin
RU2775490C2 (ru) Химерные белки на основе tigit и light
HK40091905A (zh) 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
HK40092182A (zh) 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]